Live audio of the webcast will be accessible by visiting the Events section of Day One’s Media & Investors page. An archived ...

Plants have considerable potential for the production of biopharmaceutical proteins and peptides because they are easily transformed and provide a cheap source of protein. Several biotechnology ...

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...

Identifying biopharmaceuticals with the potential to be formulated as pills just became easier, according to researchers who used artificial intelligence to find drugs stable enough for oral delivery.

- Kevin Li, M.D., from Frazier Life Sciences will join the Board of Directors ...

Management projected full-year 2025 net product revenues of $140 million to $150 million for OJEMDA, citing "strong and persistent demand, deepening prescriber adoption, and consistent payer coverage" ...

CEO Jeremy Bender highlighted the strong performance of OJEMDA, with Q1 2025 net product revenue reaching $30.5 million, driven by a 16% increase in quarterly scripts compared to the prior quarter. He ...

From life-saving vaccines to advanced cancer therapies, biopharmaceuticals are quietly transforming modern medicine. Made ...

Day One Biopharmaceuticals reported $29 million in Q4 2024 revenues, ending the year with $531.7 million in cash. Day One Biopharmaceuticals reported significant financial results for the fourth ...

Paradigm Biopharmaceuticals Ltd. has announced changes in the director Paul Rennie’s interest in securities, highlighting the acquisition of 1.7 million performance rights set to expire in December ...

Preclinical data show Clover’s protein-based adjuvanted COVID-19 vaccine candidate, S-Trimer, induces a strong neutralizing immune response in animalsand protects nonhuman primates from SARS-CoV-2 ...

Day One Biopharmaceuticals, Inc. (DAWN) closed the last trading session at $11.16, gaining 26.1% over the past four weeks, ...